Superscan prostate cancer. 53347/rID-84471 About 3 out of 4 men with a raised PSA level will not have cancer. This long path length of beta particles of 177 Lu precludes its use in certain patterns of disease, particularly diffuse prostate cancer metastasis to the bone marrow in a superscan pattern, as this may result in severe bone marrow toxicity in patients who may already have a compromised bone marrow reserve . Authors Yuxin Li 1 A 74-year-old man presented to the Andrology Clinic for management of potential complications of androgen deprivation therapy for prostate cancer. Bone scan revealed diffuse skeletal metastases with superscan appearance. 3. 5 months later, an F-fluciclovine PET/CT was performed despite of a decreased PSA of 0. A superscan pattern on the initial whole-body bone scan Prostate cancer is the most common malignancy associated with superscan along with others such as lung cancer, breast cancer and haematological malignancies. A superscan on Prostate cancer is the second most common malignancy in men worldwide, with a good prognosis when is detected and treated in early stages, but, when it presents progression to castration-resistant We describe the finding of a metastatic superscan detected by Ga-PSMA PET/CT imaging. The patient received three out of a planned six cycles of radium-223 before it was discontinued due to myelosuppression requiring multiple blood transfusions, and The pattern of diffuse increased skeletal uptake with no tracer seen in the kidneys/bladder is called a "superscan". It means the cancer is in all bones and bone marrow. 73% (33/46) prostate cancer patients with superscan had Gleason score of 8 and above 8 with mean serum prostate-specific 1 INTRODUCTION. These figures are for people diagnosed between 2013 and 2017. malignancy associated with superscan along with others such as lung cancer Annually, >1. Prostate cancer that spreads to the bones can cause pain and broken bones. gov means it’s official. At the 3 Presentation. degenerative disease, osteoporosis) When to switch treatment: Defining Progression. S. Nuklearmedizin 1998; 37:156-158. Prostate cancer (PCa) remains one of the most common cancers in men and incidence is increasing in recent years [1, 2]. Most of these deaths are due to advanced-stage disease. Case study, Radiopaedia. Age, prostate-specific antigen (PSA), free/total PSA (f/tPSA), PSA density (PSAD), peripheral zone Imaging of metastatic castrate-resistant prostate cancer to select patients suitable for peptide receptor radioligand therapy can be performed with both SPECT and PET PSMA radiotracers. A high PSA (also called raised PSA or elevated PSA) can be a sign of common prostate problems which are not related to cancer, such as prostatitis, or even a urine infection. renal cell carcinoma. Bone The total counts acquired during the scan were used to compare the skeletal uptake of the radiopharmaceutical between prostate patients showing superscan image patterns (n=38), prostate cancer Results. In addition to androgen-deprivation therapy (ADT), new generation agents have provided survival advantages to patients with metastatic hormone-sensitive PC (mHSPC). Secondaryefficacyendpoints included time to castration Learn enough about prostate cancer to feel comfortable making treatment decisions. Methods An international expert The SEER database tracks 5-year relative survival rates for prostate cancer in the United States, based on how far the cancer has spread. A superscan pattern on the initial whole-body bone scan suggested Aim: The risk of failing to recognize the false, normal pattern of the superscan is a real one, with potential consequences for diagnosis and treatment. Superscan pattern of F-18 sodium fluoride PET/CT study in a case of prostate cancer Clin Nucl Med. The diagnosis was bone metastases from prostate cancer. 2%)), high C The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have demonstrated the application value of positron Bailly M, Besse H, Kerdraon R, Metrard G, Gauvain S. A superscan on Tc-99m bone scintigraphy is described in multiple skeletal metastatic disease. No study has specifically assessed its safety in patients with extensive skeletal metastases of mCRPC. (2014) 39:912–4. 18F-FDG is the Incidence of superscan in prostate cancer was 14. org/10. A 63-year-old man with metastatic prostate carcinoma underwent Ga-PSMA PET/CT Prostate cancer is a bone tropic disease, leading to pain, reduced quality of life, fractures, functional decline, impairment of hematopoiesis, and reduced survival. . @article{Chen2021SuperscanSO, title={Superscan: Superiority of xSPECT/CT over OSEM SPECT/CT in bone scans of prostate cancer patients. PubMed Background: Prostate cancer (PC) is one of the most common cancer types in men. org (Accessed on 13 Nov 2023) https://doi. JL is currently funded by a Prostate Cancer Foundation grant, NIH grant R01 CA185297, and US Department of Defense Prostate Cancer Research Program grant W81XWH-19-1-0686. None of the patients were lost to follow-up during this analysis. The frequency of superscans ranged from 1. A super bone scan may result Keywords: Prostate cancer; Ga-68 PSMA; Superscan Case Report Prostate cancer (PCa) is the most frequent tumor in men worldwide and prostate cancer most often spreads to bone, commonly leading to bone pain [1]. Afterward, radiotherapy for bone lesions was arranged and the effects were evaluated. It is We observed superscan pattern in a 70-year-old patient with an ele-vated PSA serum level at 638 ng/mL of a prostate cancer after che-motherapy (Figure 1). A 63-year-old man with metastatic prostate carcinoma underwent Ga-PSMA PET/CT imaging for staging and evaluation of the most appropriate therapeutic option. The whole-body image count alone, with little or no additional processing, is a helpful discriminator for the nuclear medicine superscan and may assist the identification of this relatively uncommon diffuse metastatic disease in men with prostate cancer and reduce the number of investigations that might otherwise be reported incorrectly. Baseline skeletal survey. Bone is the most common site of metastasis, DOI: 10. To determine the incidence and clinical significance of this so-called flare phenomenon, serial bone scans were reviewed in 33 patients with carcinoma of the The objective of this study was to evaluate the rate of detection of bone metastases obtained with the prostate-specific membrane antigen (PSMA)–targeting tracer 99mTc-MIP-1427, as opposed to conventional bone scanning with 99mTc-methylene diphosphonate (99mTc-MDP), in a collective of patients with known advanced-stage Prostate cancer staging traditionally includes computed tomography for assessment of lymph nodes and technetium-99m bone scintigraphy for assessment of bone metastases. The SEER database, however, doesn’t group cancers by AJCC TNM stages (stage 1, stage 2, stage 3, etc. score for clinically significant prostate cancer (csPCa). x-ray. His prostate-specific antigen levels were >1000 ng/mL, and prostatic magnetic resonance imaging showed an enlarged prostate with a heterogeneous signal PDF | On May 1, 2014, M. According to “Global Cancer Statistics 2022”, prostate cancer is the second most common cause of malignancy amongst men, with an annual incidence of 1. prostatic carcinoma; breast cancer; transitional cell carcinoma (TCC) Based on the development of new treatments for advanced prostate cancer, the recommendations regarding measurement of progressive disease or response to therapy continue to be assessed. This was despite treatment with a r Few clinical and preclinical articles reported the potential usefulness of 18 F-choline PET/CT in several hematological proliferative diseases. Abdominal CT showed hepatomegaly with mu prostate cancer (most common in males) breast cancer (most common in females) non-small cell lung cancer. Z. The patient Purpose Actinium-225-labeled prostate-specific membrane antigen ([²²⁵Ac]Ac-PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer is the most common . com Received Date: 15 Dec 2020 LBA4 Background: Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains invariably fatal. Out of 6027 patients referred for bone scan, 307 patients had prostate cancer on histopathological examination. It is the second most common cancer among males in the U. For the evaluation of Superscan is when the bone scan lights up everywhere. 712 in Colombia for 2018 ( 1 intermediate >6, and high burden in the presence of diffuse disease (superscan). Clinical Progression • Bone pain in elderly patients with advanced prostate cancer can also have other causes (e. Patients and methods: Two trials that used PCWG-2 guidelines to define progression were analysed: a randomized phase Bickle I, Superscan: prostate cancer. Here we present the case of a 41 year old woman with carcinoma colon with metastatic superscan on (99m)Tc-MDP bone scintigraphy, a very rare cause for metastatic superscan. A: Restaging PET-CT in a 74-year-old male with history of prostate carcinoma diagnosed 3 years ago treated with radiation, currently with rising PSA and most recent level of Terminology. Prostate Cancer (PCa) is a common tumor of the urinary system and one of the major malignant tumors threatening men’s health in the world []. Who was referred for The pattern of diffuse increased skeletal uptake with no tracer seen in the kidneys/bladder is called a "superscan". }, author={Ew-Jun Super bone scan is a special condition of extremely high bone uptake relative to soft tissue with absent renal radioactivity visualisation (‘absent kidney sign’). The risk of prostate cancer increases with age. For instance, the incidence of prostate cancer in China is showing a continuous increase and therefore is gradually affecting men’s health []. 2 million new cases of prostate cancer are diagnosed and global prostate cancer-related deaths exceed 350 000 per annum, making it one of the leading causes of cancer-associated death in men. Basically, the entirety of the contrast medium ends up in the bone, and none ever makes major category of prostate cancer: localised, locally advanced and advanced (Figure 1). Skeletal superscan on 18F-FDG PET/CT in a case of acute Please see the Editorial Comment by Sungmin Woo discussing this article. The Prostate Cancer (PCa) Guidelines Panel have prepared this guidelines document to assist medical professionals in the evidence-based management of PCa. Diffuse metastasis, which is not infrequent in prostate cancer, can also be suspected on the basis of a 'super scan'. 108998 Corpus ID: 219762264; Superscan: Superiority of xSPECT/CT over OSEM SPECT/CT in bone scans of prostate cancer patients. 39%). hepatocellular carcinoma. Two years This report presents the imaging findings in a patient with advanced prostate cancer and bone metastases. However, patients with diffuse bone involvement, diagnosed with a "superscan" by bone scintigraphy at baseline, were excluded due to a lack of efficacy The . This appearance can result from a range of etiological factors: diffuse metastatic disease. 17 Study Assessments OSwastheprimaryendpoint. Stage 1 Epidemiology. The diagnosis is usually established by a Lower your risk for prostate cancer. 1 It was estimated that, in 2021, 248,530 new PCa cases were projected to be diagnosed in the United States accounting for 26% of all organically sourced tumors in men. 68 Ga-PSMA ligand in PET/CT revealed a PSMA over expression of diffuse sclerotic lesions extended • Malignant superscan not uncommon in advanced disease. Crossref. With metastatic disease (most commonly prostate or breast cancer), the uptake is heterogeneous or patchy and favours the axial skeleton. Physical examination revealed generalised bone tenderness with associated indirect pain; digital rectal examination indicated asymmetric prostatic induration. Nearly all types of cancer can metastasize to the bones, but some types of cancer are particularly prone to metastasize to bone, for example, prostate cancer, breast cancer and renal cancer (Huang et al. Before sharing sensitive information, make sure you’re on a federal government Technetium-99m methyl diphosphonate bone superscan. Prostate cancer tends to be slow-growing and slow to spread. If prostate cancer is suspected based on results of screening tests or symptoms, tests will be PRLT with <sup>177</sup>Lu-PSMA is well-tolerated and effective in metastatic prostate cancer patients who have no other treatment options available. The novel prognostic markers found in this study (high platelet count, superscan pattern) were associated with poor overall survival. A bone scan with diffused increased skeletal tracer uptake relative to soft tissue, combined with faint renal activity is known as a superscan. Liver. However, this phenomenon in nuclear medicine has several other causes that need to Positron emission tomography/computed tomography (PET/CT) is widely used in prostate cancer to evaluate the localized tumor burden and detect symptomatic metastatic lesions early. The open-label study enrolled patients with progressive mCRPC based on at least 1 of the following per The Prostate Cancer Clinical Trials Working Group 3: serum or superscan on bone scan Who treats prostate cancer? The main types of doctors who treat prostate cancer include: Urologist: A surgeon who treats diseases of the urinary system and male reproductive system (including the prostate) Radiation oncologist: A doctor who treats cancer with radiation therapy Medical oncologist: A doctor who treats cancer with medicines, such Recent advances in the fundamental understanding of the complex biology of prostate cancer have provided an increasing number of potential targets for imaging and treatment. The patient responded well to definitive treatment, exhibiting clinical improvement based on decreased PSA le If the kidneys and bladder are not seen, this should raise suspicion of the so-called “superscan. Recent advances in the fundamental understanding of the complex biology of prostate cancer have provided an increasing number of potential targets for imaging and treatment. Currently, the main treatment modality for newly diagnosed metastatic PCa is androgen deprivation therapy (ADT), followed by chemotherapeutic agents (). Bones. We describe the finding of a metastatic superscan detected by Ga-PSMA PET/CT imaging. Prostate-specific membrane antigen (PSMA) is a cell surface protein with high ESMO 2022 177-Lutetium (Lu)-PSMA for prostate cancer treatment, 68Ga-PSMA-11 PET/CT + Lu-PSMA therapy, diagnostics and treatment of prostate cancer, Lu-PSMA in prostate cancer, TheraP trial, VISION trial, post-androgen receptor pathway inhibitor. Introduction. Incidence of superscan in prostate cancer was 14. prostatic carcinoma; breast cancer; transitional cell carcinoma (TCC) Most prostate cancers are first found as a result of screening. mil. Apart from prostate cancer, which is the most common condition associated with a superscan, other malignancies like breast cancer, lung cancer [1] [2] [3][4] can cause superscan appearance on bone Request PDF | FDG Hepatic Superscan Caused by Massive Breast Cancer Invasion | A 46-year-old woman who was treated in the past for locally advanced breast cancer, presented with signs of acute The most significant factors associated with the «superscan» scintigraphy phenomenon in prostate cancer patients were the primary tumor extension, high PSA level and low-grade tumors. A 76-year-old man presented with recently diagnosed prostate adenocarcinoma, Gleason score of 4 + 4, and a Super bone scan with concurrent PSA of 1. Images demonstrated diffuse and extensive skeletal uptake Preliminary efficacy and safety results from the TATCIST trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer Ebrahim S. Conclusion: Superscan is most frequently seen in prostate cancer, but numerous other cancers and metabolic bone diseases can cause superscan, which should be kept in mind when encountering an unexpected superscan on BS. The images show a striking resemblance to a bone scan, with unusual liver uptake. No bony pain or weight loss. Learn as much as you need to know about your cancer and its treatment in order to understand what to expect from treatment and life after treatment. Talk to your doctor about your risk factors and when or if you should be screened for In prostate cancer, the bone is the most common site of metastasis, and it is essential to evaluate metastatic bone lesions to assess the tumor burden and treatment response. This is a report of bone scintigraphy demonstrating superimposed metastatic and metabolic superscan in a patient with prostate cancer, who subsequently developed renal osteodystrophy. A 76-year-old man presented with recently diagnosed prostate Keywords: Superscan, prostate carcinoma, 18F PSMA PET/CT, 18F prostate-specific membrane antigen. (See Screening Tests for Prostate Cancer. The aim of prostate MRI is to detect clinically significant prostate cancer, as insignificant prostate cancer is common 35. A 72-year-old man with a history of metastatic prostate cancer is referred for a bone scan because of pain in the left shoulder and lower neck ( Among papers with malignant cause, prostate cancer was the most common cause, followed by gastric cancer. 1097/RLU. , more than 75% of the ribs, vertebrae, and pelvic bones). We report and incidental finding of a superscan-like pattern in a patient affected by essential thrombocythemia (ET), performing 18 F-choline PET/CT for a biochemical recurrence of prostate cancer. A skeletal ‘superscan’ in patients with prostate cancer has been A superscan is an imaging appearance on a Tc-99m diphosphonate bone scan which occurs as a result of a high ratio of bone to soft tissue tracer accumulation. 0b013e3182291c3d. 18F-FDG PET/CT superscan in prostate cancer. 1 Following lymph nodes, bone metastasis becomes the second most prevalent site of metastasis in prostate cancer, affecting approximately 90% of individuals with Terminology. Metabolic . In time it is likely that the PCWG3 recommendations will heavily influence the development of clinical trials for M0 and M1 patients with CRPC. 2 Since the absent or faint activity in the genitourinary tract is known as a ‘superscan’. or MRI may be necessary. The surgical F-FDG PET/CT of a patient with inflammatory lower back pain reveals diffuse bony metastases, similar to the "superscan" found on a Tc-methylene diphosphonate scintigraphy, and also demonstrates a prostatic lesion which appears to be a poorly differentiated prostate adenocarcinoma. It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has changed radically in recent years. Nearly all types of cancer can metastasize to the bones, but some types of cancer are particularly (A) A 64-year-old male patient with metastatic prostate carcinoma was subjected to Gallium-68 (68 Ga) prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT). e. 2 Therefore, significant renal and bladder radioactivity are normal in most scans. The superscan imaging appearance occurs as a result of a high ratio of bone to soft tissue tracer accumulation. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Multiple abnormal foci were observed in the axial and appendicular skeleton, which were suggestive of metastatic superscan from prostate cancer. Lung cancer, breast cancer, renal cell carcinoma, and prostate cancer account for ~80% of all bone metastases 1. We aimed to investigate the hematologic The radionuclide bone scan 3 months after the initiation of treatment for advanced cancer of the prostate occasionally shows apparent progression of individual lesions despite clinical improvement. diffuse metastasis, commonly seen in prostate cancer or breast Purpose: Actinium-225-labeled prostate-specific membrane antigen ([225 Ac]Ac-PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A Superscan fluciclovine PET/CT A 69-year-old man with prostate cancer presented to the hospital with 2 weeks' history of fever, abdominal distension, and fatigue. The new prostate-specific membrane antigen (PSMA) PET imaging will significantly A 'SUPERSCAN' for prostate cancer could be used to launch a much-needed national screening programme, scientists will suggest today. Bone is the most common site of metastasis, F-FDG PET/CT of a patient with inflammatory lower back pain reveals diffuse bony metastases, similar to the "superscan" found on a Tc-methylene diphosphonate scintigraphy, and also demonstrates a prostatic lesion which appears to be a poorly differentiated prostate adenocarcinoma. Most people with stage I prostate cancer don’t show any symptoms. Superscan pattern of F-18 sodium fluoride PET/CT study in a case of prostate cancer. Survival by stage. 41 million. Ji Prostate Cancer UK Online Community » Treatment » Advanced or metastatic cancer » Dad diagnosed with advanced PC, I'd never heard of a 'Superscan' either but after looking it up its a bone scan where over 75% of the bones have mets. The purpose of the study is to find out the overall incidence of superscan among different type of cancers, causes of superscan and its relationship with other Purpose Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior Prostate Cancer Clinical Trials Working Groups. Two years after the first bone scintigraphy showing multiple metastases, the patient developed renal insufficiency, hyperphosphoremia, and hypocalcemia. However, specific primary tumour features might impact accuracy of PSMA-PET for PCa detection. Age: 65 years. Radiolabeled small molecules that bind with high affinity to its active extracellular center have emerged as a potential new diagnostic standard of reference for prostate cancer, resulting in images with Introduction. 7 ng/mL. The gamma rays can be "seen" by using a special camera, which produces Prostate cancer is one of the most common cancers affecting men. )Early prostate cancers usually don’t cause symptoms, but more advanced cancers are sometimes first found because of symptoms they cause. Prostate cancer (PCa) is the most frequent tumor in men worldwide. Prostate cancer is a serious disease, but early detection is key. }, author={Ew-Jun DOI: 10. Bailly and others published Le superscan métabolique en TEP/TDM au 18F-FDG : à propos d’un cas de cancer de prostate | Find, read and cite all the research you need on PET Superscan can be seen in Fluciclovine scan. Clin Nucl Med 2011; 36:1046–1048. However, little is known about the clinical outcome of surgery for MSCC from PC. Bone scintigraphy (BS) using 99mTc-labeled methylene diphospho-nate (99mTc-MDP) remains the recommended imaging modality for the detection of bone metastases in patients with prostate cancer (PCa). The 15-minute MRI scan uses magnetic waves with no radiation [43] Li reports a case of metastatic recurrence of prostate cancer that revealed a superscan appearance on 18 F-NaF scintigraphy, with intense uptake in the axial skeleton and poor visualization Overall incidence of superscan in this study was 1. With diffuse bone metastases, a "superscan" may be seen; this superscan demonstrates high uptake throughout the skeleton, with What the Kattan Nomograms Can Tell You. prostate cancer, Superscan, bone metastasis, bone scan, fluciclovine PET/CT Search for Similar Articles You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search. Due to the early detection of disease, most patients have a localized disease at initial diagnosis; however, distant metastasis can occur in 35% of cases during follow-up []. Out of 307 patients with prostate cancer, 46 had superscan appearance. However, a primary concern are false negatives ESMO 2022 177-Lutetium (Lu)-PSMA for prostate cancer treatment, 68Ga-PSMA-11 PET/CT + Lu-PSMA therapy, diagnostics and treatment of prostate cancer, Lu-PSMA in prostate cancer, TheraP trial, VISION trial, post-androgen receptor pathway inhibitor. ” A superscan implies diffusely increased osseous uptake due to metastatic disease (most commonly breast or prostate cancer) or metabolic bone disease which is so intense that little or no renal excretion of the radiotracer occurs. The new prostate-specific membrane antigen (PSMA) PET imaging will significantly improve how prostate cancer is detected and treated. Unfortunately, these treatment Objective: To investigate the association of radiographic progression defined by Prostate Cancer Working Group (PCWG)-2 guidelines and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). This changed when studies showed that the addition of docetaxel chemotherapy or abiraterone acetate to ADT Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in prostate cancer. There are four main stages of prostate cancer, and stage 4 often involves bone metastases. Early detection of metastatic bone disease and the definition of its extent, pattern, and aggressiveness are crucial for Incidence of superscan in prostate cancer was 14. However, this term is without a consensus definition 35,36 (c. Methods: Eight face-to-face meetings were convened over 3 years to create the The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have demonstrated the application value of positron Bailly M, Besse H, Kerdraon R, Metrard G, Gauvain S. Histology demonstrated infiltrating adenocarcinoma and a Gleason score of 8 (4 + 4) with perineural infiltration. Request PDF | Superscan Imaging on Ga-68 PSMA PET/CT in Prostate Cancer Patient | Prostate cancer (PCa) is the most frequent tumor in men worldwide. The appearance of a metastatic superscan differs from that of a metabolic superscan. Having a family history of prostate cancer. In 2018 alone, nearly 1. Location The final images of the patient that demonstrated a superscan appearance in the Gallium-68 PSMA positron emission tomography/computed tomography, which is a rare phenomenon, are presented. We present a 70-year-old patient with an elevated PSA serum level of 638 ng/mL after chemotherapy for prostate cancer. Key Words: prostate carcinoma, 68Ga-PSMA PET/CT, superscan FIGURE 1. 9 % of Prostate biopsy revealed adenocarcinoma. 82), positive bone scan (0. Early detection of metastatic bone disease and the definition of its extent, pattern, and aggressiveness are crucial for Prostate cancer is the second most commonly diagnosed cancer in males, only behind skin cancer. 177Lu-PSMA-617 is a targeted radioligand therapy that delivers ß-particle radiation to PSMA-expressing cells and surrounding Purpose Prostate-specific membrane antigen (PSMA-) PET has become a promising tool in staging and restaging of prostate carcinoma (PCa). Positron emission tomography (PET) combined with computed tomography (PET/CT) or magnetic resonance imaging (PET/MRI) using several radiopharmaceuticals—particularly prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals—are new-generation imaging modalities for prostate cancer (PC) Pathogenetic differentiation of the bone superscan using bone marrow scintigraphy. 0000000000000376. 2020. 78). 3 million new cases of prostate cancer were reported worldwide. 73% (33/46) prostate cancer patients with superscan had Gleason score of 8 and above 8 with mean serum prostate-specific Metastatic Prostate Cancer Showing Superscan on Radionucleotide Imaging OPEN ACCESS *Correspondence: Jatinder Kumar, Department of Urology, University of Florida, Jacksonville, Florida, USA, Tel: 904-699-7488; E-mail: Jatinderurology82@gmail. Methods The demographic and clinical characteristics of 956 patients were recorded. 73% (33/46) prostate cancer patients with superscan had Gleason score of 8 activity is known as a superscan (Manohar et. PCa bone metastasis is mainly osteosclerotic 1 INTRODUCTION. Prostate cancer is the second most common malignancy in men worldwide, with a good prognosis when is detected and treated in early stages, but, when it presents progression to castration-resistant metastatic prostate cancer, most of the cases will have bone metastasis, decreasing the quality of life and life expectancy. He had a rising prostate-specific antigen with a concurrent rise in alkaline phosphatase and bone remodeling markers. Urinary urgency and frequency with high PSA level. A study of 307 prostate cancer patients reported that 15% demonstrated superscan appearances, of which 72% of the same group (15%) had serum PSA levels We describe a case series of seven patients with prostate cancer from the National Institute of Cancerology in Colombia, in which a super scan pattern was found This report presents the imaging findings in a patient with advanced prostate cancer and bone metastases. Bone scan is part of the staging modality commonly used to evaluate bone metastasis. Superscan is intense symmetric activity in the bones with diminished renal and soft tissue activity on a Tc diphosphonate bone scan. 7 ng/mL; a Superscan fluciclovine PET/CT was identified, and bone metastasis were later confirmed at biopsy. [German]. Author information Prostate cancer is one of the types of cancer that is most likely to spread, or metastasize, to bones. Abstract. Manohar PR, Rather TA, Khan SH, Malik D. 98% (46/307), and 71. For imaging, they use a different ligand, PSMA Prostate cancer cells that spread past the prostate most often go to the: Lymph nodes. Stage III and IV tumors were detected in 97. In this analysis, we aimed to determine the most effective approach for treating and He declined chemotherapy and was treated with radium-223, an alpha particle emitting radionuclide therapy typically used in metastatic castrate-resistant prostate cancer. Prostate cancer is one of the most common cancers affecting men. This is related to a poor prognosis and is one of the major causes of morbidity and mortality in such patients. 3% in different type of cancer patients, and the most common cause of Superscan appearance was prostate cancer. The nomogram predicts the likelihood, in a man initially treated with surgery, that he will die of prostate cancer five, ten, and 15 years from the time his PSA begins to rise. Laboratory tests were assessed before, during, and after 223Ra treatment with ANC, Hb, PC, prostate specific antigen Participants with skeletal metastases presented as a superscan on a ⁹⁹ᵐTc bone scan. Imaging of metastatic castrate-resistant prostate cancer to select patients suitable for peptide receptor radioligand therapy can be performed with both SPECT and PET PSMA radiotracers. Tafti BA, Shaba W, Berenji GR. The PSA level corresponded well with the diagnosis of prostate cancer and a positive bone scan but moderately well with Gleason score as shown by AuROC for diagnosis of prostate cancer (0. Prostat spesifik antijen düzeyi >1000 ng/mL idi ve prostat manyetik rezonans In prostate cancer, bone is the second most common site of metastatic disease after lymph nodes. The 177 Lu-labeled prostate-specific membrane antigen (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate cancer is under investigation in a phase III trial (VISION: NCT03511664). Laboratory findings showed signs of acute liver failure, and In prostate cancer, bone is the second most common site of metastatic disease after lymph nodes. These tracers accumulate in certain organs and tissues, such as bones, and give off a type of radiation called "gamma" radiation. , hepatic The frequency of new cases of prostate cancer reported by The Global Cancer Observatory was 12. and 4 = “superscan” or its equivalent (i. }, author={Ew-Jun Superscan in 68 Ga-PSMA ligand PET/CT is not very commonly encountered in prostate cancer patients. Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations. 3% in a cohort Superscan findings open a new way towards targeted therapy with 177Lu-PSMA-617 for disease control in advanced cases of castration resistant prostate The . Laboratory examination revealed high serum alkaline phosphatase (1348 U/L (bone type, 73. This patient had a known history of prostate cancer with an elevated PSA of 45 ng/mL. It is located inside the pelvis and wrapped around the urethra, the tube leading from the bladder outside the body that drains urine through the penis. His prostate-specific antigen levels were >1000 ng/mL, and prostatic magnetic resonance imaging showed an enlarged prostate with a heterogeneous signal Terminology. However, PET/CT using prostate This report presents the imaging findings in a patient with advanced prostate cancer and bone metastases. }, author={Ew-Jun A 76-year-old man presented with recently diagnosed prostate adenocarcinoma, Gleason score of 4 + 4, and a Super bone scan with concurrent PSA of 1. In Colombia, This is a report of bone scintigraphy demonstrating superimposed metastatic and metabolic superscan in a patient with prostate cancer, who subsequently developed renal osteodystrophy. Gender: Male. Scintigraphy This nomogram can be used by patients to estimate the risk of dying of prostate cancer if their cancer recurs, signaled by a rising PSA, after radical prostatectomy. 1 Despite major improvements in the systemic treatment of advanced prostate cancer, metastatic prostate cancer remains Superscan Causes of Superscan • Metastatic disease – Prostate, breast, lung most common. Only three out of eight patients who died of diseases other than prostate cancer had an observation time shorter than 24 months (4, 10 and 12 months). , 2020). Skeletal metastases presenting as superscan on technetium 99m methylene diphosphonate whole body bone scintigraphy in The extensive innumerable osteoblastic metastases involving the axial and appendicular skeletons resulting in a superscan appearance. However, a primary concern are false negatives Introduction Prostate cancer is known to have a tendency to metastasize to bone. prostate-specific antigen (PSA) >10 Images demonstrated diffuse and extensive skeletal uptake in the axial and appendicular skeleton, corresponding to the typical red marrow distribution, in a 63-year-old man with metastatic prostate carcinoma. A technetium-99m methyl diphosphonate bone superscan demonstrating intense, diffuse uptake in the axial and The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer Eur J Nucl Med Mol Incidence of superscan in prostate cancer was 14. The so-called “Kattan nomograms” on the Memorial Sloan-Kettering Cancer Center web site are a set of tools that allow you and your doctors to do three different things, depending on where you are along the possible pathway from initial diagnosis to hormone refractory disease: If you have Prostate cancer is the most common malignancy associated with superscan along with others such as lung cancer, breast cancer and haematological malignancies. Intense osteoblastic activity in the bones causes diminished renal and background soft t Survival for prostate cancer is generally good, particularly if you are diagnosed early. The final images of the patient that demonstrated a superscan appearance in the Gallium-68 PSMA positron emission tomography/computed tomography, which is a rare phenomenon, are presented. Find out if you need one. 88), and Gleason score>7 (0. Certain sports and medications may also temporarily affect PSA levels. Although PET radiotracers generally have higher sensitivity and spatial resolution, SPECT tracers can be an effective alternative when PET/CT systems This is a report of bone scintigraphy demonstrating superimposed metastatic and metabolic superscan in a patient with prostate cancer, who subsequently developed renal osteodystrophy. A 63-year-old male patient presented with metastatic prostate cancer. gov or . radphyschem. This procedure did not prolong patient handlin</p> Bickle I, Superscan: prostate cancer. , 1988). Parida GK, Soundarar ajan R, Passah A, Bal C, Kumar R. A. A 76-year-old man presented with recently diagnosed prostate A bone scan uses tiny amounts of radioactive materials called tracers (or properly "radionuclides") that are injected into the patient. 000ug/L) transrectal prostate biopsy: multifocal prostatic adenocarcinoma bone marrow biopsy: heavily infiltrated with tumor cells (most probably of prostate origin) based on the history of multifocal prosta Li reports a case of metastatic recurrence of prostate cancer that revealed a superscan appearance on 18 F-NaF scintigraphy, with intense uptake in the axial skeleton and poor visualization of the Metastatic bone disease (MBD) is common—it is detected in up to 65–75% of patients with breast or prostate cancer, in over 35% of patients with lung cancer; and almost all patients with symptomatic multiple myeloma have focal lesions or a diffuse bone marrow infiltration. Biyopsi ile kanıtlanmış 70 yaşındaki prostat karsinomu olan hasta, radyonüklid bazlı tedavi için nükleer tıp bölümüne yönlendirildi. 73% (33/46) prostate cancer patients with superscan had Gleason score of 8 and above 8 with mean serum prostate-specific sensitive prostate cancer, treatment intensification with darolutamide, androgen-deprivation therapy, and docetaxel increased OS with a similar AE increased skeletal metastases with superscan. Risk factors. There are no UK-wide statistics available for prostate cancer survival by stage. Factors that can increase the risk of stage 4 prostate cancer include: Getting older. F-FDG PET/CT of a patient with inflammatory DOI: 10. Image courtesy of Radiopaedia. “For prostate cancer to cause symptoms, it may be at an advanced stage A 76-year-old man presented with recently diagnosed prostate adenocarcinoma, Gleason score of 4 + 4, and a Super bone scan with concurrent PSA of 1. 2024) and has been defined as one or more of the following (noting variability within criterion) 31-35:. The bone scan flare phenomenon appeared within a short time after radiotherapy. g. 73% (33/46) prostate cancer patients with superscan had Gleason score of 8 and above 8 with mean serum prostate-specific The most significant factors associated with the «superscan» scintigraphy phenomenon in prostate cancer patients were the primary tumor extension, high PSA level and low-grade tumors. 1 About 40–60% of the injected Tc-99m MDP is excreted in the urine. Androgen deprivation therapy (ADT) alone was for decades the standard of care for treating mHSPC. Quantitative indices of bone We describe a case series of seven patients with prostate cancer from the National Institute of Cancerology in Colombia, in which a super scan pattern was found We describe the finding of a metastatic superscan detected by Ga-PSMA PET/CT imaging. A 64-year-old male patient with metastatic prostate carcinoma diagnosis received lutetium-177 prostate-specific membrane antigen Positron emission tomography (PET) combined with computed tomography (PET/CT) or magnetic resonance imaging (PET/MRI) using several radiopharmaceuticals—particularly prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals—are new-generation imaging modalities for prostate cancer (PC) DOI: 10. Prostate-specific membrane antigen (PSMA) is highly expressed in mCRPC lesions. Diagnosis. We investigated histopathological parameters and immunohistochemical PSMA The whole-body image count alone, with little or no additional processing, is a helpful discriminator for the nuclear medicine superscan and may assist the identification of this relatively uncommon diffuse metastatic disease in men with prostate cancer and reduce the number of investigations that might otherwise be reported incorrectly. The PSA a Maximum intensity projection image revealed evidence of hypermetabolic malignant large left thyroid lobe lesion (arrowhead), associated with few hypermetabolic metastatic mediastinal lymphadenopathy (curved arrow), several hypermetabolic bone marrow lesions (asterisks), and hypermetabolic massive hepatomegaly (i. Two years after the first bone scintigraphy showing multiple metastases, the patient developed renal insufficiency, hyperphosphoremia, and Prostate cancer is a type of cancer that develops in the prostate, a small walnut-shaped gland in the male reproductive system. thyroid cancer. org (Accessed on 15 Nov 2023) https://doi. A skeletal ‘superscan’ in patients with prostate cancer has been demonstrated This report presents the imaging findings in a patient with advanced prostate cancer and bone metastases. – Multiple myeloma and renal adenocarcinoma usually do not show increased uptake. This patient had a known history of prostate cancer with an We describe the imaging features of a metastatic superscan on gallium-68 Glu-NH-CO-NH-Lys-(Ahx)-[Ga-68(HBED-CC)], abbreviated as gallium-68-prostate-specific membrane The «superscan» phenomen was found to occur most often in prostate cancer patients aged 60-69 years. F-FDG PET/CT of a patient with inflammatory gastric cancer and up to 23% in a cohort of prostate cancer patients. However, histopathological examinations (from bone 18F-FDG PET/CT of a patient with inflammatory lower back pain reveals diffuse bony metastases, similar to the “superscan” found on a 99mTc-methylene diphosphonate scintigraphy, and also demonstrates a prostatic lesion which appears to be a poorly differentiated prostate adenocarcinoma. Patient Data. Antiandrogens and GnRH antagonists were administered. PubMed Purpose Prostate-specific membrane antigen (PSMA-) PET has become a promising tool in staging and restaging of prostate carcinoma (PCa). This is referred to as a superscan, as seen in the anterior and posterior images on the right (note the lack of renal or soft tissue activity). Validated prediction models for PCa-specific mortality (PCSM) in this population are needed for treatment decision-making and clinical trial design. , 2016). prostate-specific antigen (PSA) >10 Purpose Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior Prostate Cancer Clinical Trials Working Groups. However, a primary concern is the false negatives associated with additional xSPECT reconstruction algorithm in four prostate cancer patients with high Prostate-Speci%c Antigen (PSA) levels, which initially showed relatively normal %ndings on planar images. The imaging was performed 60 min after intravenous administration of 5 mCi (435 mBq) Ga-68 PSMA in the craniocaudal A biopsy-proven patient with prostate carcinoma aged 70 years was referred to the department of nuclear medicine for radionuclide-based therapy. Offering breakthrough diagnostics for prostate cancer treatment Prostate cancer is one of the most common cancers in men. A superscan pattern on the initial whole-body bone scan suggested extensive disease. Bone metastases develop when cancer cells spread from their original site to the bone. Pathology. Prostate cancer is the most common condition frequently associated with a superscan (Soloway et al. ). A 63-year-old man with a history of prostate cancer (Gleason score, 9/10) received brachytherapy 2 years ago. Skeletal scintigraphy can be used to show multiple lesions. Once prostate cancer has spread to other areas of the body, it may still respond to treatment <p>In patients with high-risk prostate cancer presenting with PSA < 80 µg/l and absent clinical symptoms, vertex to mid-thighs 3-FOV-SPECT/CT was representative for the entire skeletal system and was able to detect more lesions than planar acquisition. Laboratory findings showed signs of acute liver failure, and marked elevation of lactate dehydrogenase and tumor marker levels. Clin Nucl Med. Delpassand, 1 2Mohammad Jawed Hashmi, 2Julia Kazakin,2 A. BACKGROUND. Before sharing sensitive information, make sure you’re on a federal government site. The FDA approved the drug for positron emission tomography (PET) imaging of PSMA F-FDG PET/CT of a patient with inflammatory lower back pain reveals diffuse bony metastases, similar to the "superscan" found on a Tc-methylene diphosphonate scintigraphy, and also demonstrates a prostatic lesion which appears to be a poorly differentiated prostate adenocarcinoma. Prostate cancer is the second leading cause of cancer-related deaths in the United States. Bone metastases are the most common bone malignancy, with sclerotic bone metastases being less common than lytic bone metastases. Here we Prostate cancer is one of the most common cancers affecting men. For many people who get it, prostate cancer is less concerning 5000 Background: The availability of new agents for men with CRPC, recognition of new disease phenotypes, and an evolving regulatory environment have created the need for new CRPC clinical trial guidelines to succeed PCWG2, published in 2008. Metastatic prostate cancer (PCa) has a poor prognosis, and the incidence of metastatic PCa has increased significantly in the United States (). Survival statistics are available for each stage of prostate cancer in England. Ask your doctor, nurse or other health care professional to recommend some reliable sources of information to superscan in prostate cancer. prostate-specific antigen (PSA) >10 Prostate cancer (PCa) remains one of the most common cancers in men and incidence is increasing in recent years [1, 2]. Approximately 3. Previous or concurrent cancer that is distinct from the cancer under investigation in primary site or histology, except treated cutaneous basal cell carcinoma or squamous cell carcinoma and superficial bladder tumors. A 63-year-old man with metastatic The mean follow-up for those patients who did not die because of prostate cancer was 36 months (median, 33; range, 4–86). A positive biopsy result was found in 395 patients (35. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical Review of the PET/CT images demonstrated a “superscan” pattern of bone metastases with extensive sodium fluoride uptake in the axial skeleton, and poor visualization of distal appendicular skeleton and kidneys. 4. Background: The natural history of prostate-specific antigen (PSA)-defined biochemical recurrence (BCR) of prostate cancer (PCa) after definitive local therapy is highly variable. We investigated histopathological parameters and immunohistochemical PSMA A 75-year-old man presented with a 2-month history of worsening chest and back pain. A bone Clinical Presentation. 73% (33/46) prostate cancer patients with superscan had Gleason score of 8 and above 8 with mean serum prostate-specific The pattern of diffuse increased skeletal uptake with no tracer seen in the kidneys/bladder is called a "superscan". In order to provide prostate cancer patients with a Superscan is intense symmetric activity in the bones with diminished renal and soft tissue activity on a Tc diphosphonate bone scan. Metastatic bone disease can cause a variety of symptoms and is Prostate cancer (PCa) is the second most common malignant tumor among all malignant tumors in men and ranks first among male genitourinary tumors. 2011 Nov;36(11):1046-8. A 64-year-old male patient with metastatic prostate carcinoma diagnosis received lutetium-177 prostate-specific membrane antigen (PSMA) A biopsy-proven patient with prostate carcinoma aged 70 years was referred to the department of nuclear medicine for radionuclide-based therapy. KEYWORDS benign, bone Purpose This study aims to establish and validate a new diagnosis model called P. A study of 307 prostate cancer patients reported that 15% demonstrated superscan appearances, of which 72% of the same group (15%) had serum PSA levels of 178 ng/ml and 122 ng/ml in symptomatic and asymptomatic patients Prostate cancer can spread to nearby organs, such as your bladder, or travel through your bloodstream or lymphatic system to your bones or other organs. 3 ng/mL. The mild Prostate-specific antigen (PSA) is a protein made by the prostate, a walnut-shaped gland that’s part of the human male reproductive system. KEYWORDS: 68Ga-PSMA PET/CT; superscan; metastatic prostate carcinoma ’ INTRODUCTION Prostate cancer is the second most common malignancy in men worldwide after lung cancer, and the fifth leading cause of cancer mortality, appearing on average after the age of 50 and increasing its prevalence with age [1]. • The treatment algorithms presented in this document (Figures 2−4) represent a management structure that goes beyond a simple co Superscan Appearance of 68 Ga PSMA PET/CT in a Patient with Refractory Prostate Cancer Refrakter Bir Prostat Karsinomu Olgusunun 68 Ga PSMA PET/BT’de Superscan Görünümü Zehra Pınar Koç , 1, * Pınar Pelin Özcan , 1 Vehbi Erçolak , 2 and Mehmet Reyhan 3 Although prostate cancer can spread to the bones, that does not mean all men need a bone scan before deciding on therapy. 1016/j. The patient responded well to definitive treatment, exhibiting clinical improvement based on decreased PSA levels and CT findings in 6-month follow-up. org. Clin Nucl Med 2014;39:912-914. Federal government websites often end in . Omer Nawaz, Gabriella Garufi, Joanne Schindler,2 Luke Nordquist3 1Excel As cancer diagnoses go, prostate cancer is often a less serious one. I&T (Imaging and Therapy) is a ligand (a part of the drug molecule) that attaches to the PSMA protein on the cancer cell. PCa bone metastasis is mainly osteosclerotic, and is caused by a relative excess of osteoblast activity. With metabolic bone disease, the increased uptake is often more homogeneous and may extend to the distal appendicular Incidence of superscan in prostate cancer was 14. Metastatic spinal cord compression (MSCC) from prostate cancer (PC) influences not only patients’ prognosis but also their quality of life. • Metabolic disease – Renal osteodystrophy, Paget’s disease, hyperparathyroidism – Less common: Hyperthyroidism, hypervitaminosis D – Rare: Osteopetrosis A 69-year-old man with prostate cancer presented to the hospital with 2 weeks' history of fever, abdominal distension, and fatigue. 53347/rID-84471 was also seen in the prostate and multiple pelvic and abdominal lymph nodes. Methods An international expert Conclusion: Superscan is most frequently seen in prostate cancer, but numerous other cancers and metabolic bone diseases can cause superscan, which should be kept in mind when encountering an PSA: >2000ug/L (reference range ≤4. Pluvicto uses a different ligand, PSMA-617, for therapy. doi: 10. Related Links Request PDF | Coexistent Superscan and Lincoln Sign on Bone Scintigraphy | A 70-year-old man underwent Tc-methylene diphosphonate scintigraphy for staging of adenocarcinoma prostate. al. airikhbythgljyxlvhkinkztgsaqdtreexoxguayphovpznhbzlnu